MBX Biosciences, Inc. Common Stock
MBX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.80 | 0.27 | -0.05 | 0.76 |
| FCF Yield | -3.67% | -4.75% | -9.21% | -2.62% |
| EV / EBITDA | -15.71 | -17.74 | -8.17 | -27.85 |
| Quality | ||||
| ROIC | -6.16% | -9.92% | -11.26% | -7.22% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 1.00 | 0.90 | 0.95 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -20.91% | 20.11% | -40.79% | -9.56% |
| Safety | ||||
| Net Debt / EBITDA | 9.30 | 2.03 | 1.12 | 2.42 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -5,187.60 | -4,961.69 | 276.49 |